Page last updated: 2024-09-05

lenalidomide and Cancer, Second Primary

lenalidomide has been researched along with Cancer, Second Primary in 64 studies

Research

Studies (64)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	53 (82.81)	24.3611
2020's	11 (17.19)	2.80

Authors

Authors	Studies
Daver, N; DiNardo, CD; Ebert, BL; Furudate, K; Futreal, PA; Garcia-Manero, G; Guerra, VA; Gumbs, C; Hsu, JI; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Kennedy, JA; Little, L; McConkey, ME; Miller, PG; Nguyen, AT; Quevedo Barrios, VA; Ravandi, F; Sperling, AS; Takahashi, K; Wang, F; Yan, Y; Zhang, J; Zhang, L	1
Baumert, B; Borowiecka, E; Kulig, P; Machaliński, B; Milczarek, S; Osękowska, B; Paczkowska, E; Sommerfeld, K; Zdziarska, B; Łanocha, A	1
Boyiadzis, M; Franz, J; Jones, JR; Klem, ML; Lontos, K; Saleem, K; Shaikh, N; Yabes, JG	1
Bird, S; Pawlyn, C	1
Abid, MB; Afrough, A; Al Hadidi, S; Aljurf, M; Anderson, LD; Badawy, SM; Banerjee, R; Battiwalla, M; D'Souza, A; de Lima, M; Dholaria, B; Estrada-Merly, N; George, G; Gergis, U; Gowda, L; Hashmi, S; Hildebrandt, GC; Holmberg, LA; Kaur, G; Kharfan-Dabaja, MA; Kumar, SK; Lee, CH; Lekakis, LJ; Majhail, NS; Mian, H; Miller, KC; Munshi, PN; Murthy, HS; Nieto, Y; Nishihori, T; Patel, SS; Pawarode, A; Qazilbash, MH; Ragon, BK; Saad, A; Shah, MV; Shah, N; Solh, M; Strouse, C; Usmani, SZ; Vesole, DH; Wirk, B	1
Beaumont, M; Charbonnier, A; Gruson, B; Joris, M; Marmouset, V; Marolleau, JP; Merlusca, L	1
Aboulafia, DM; Hwang, DG; Peterson, JF; Sinit, RB; Vishnu, P	1
Diamond, B; Hillengass, J; Kazandjian, D; Landgren, CO; Maclachlan, K; Maura, F; Turesson, I	1
Argnani, L; Broccoli, A; Casadei, B; Cavo, M; Gentilini, M; Zinzani, PL	1
Au-Yeung, R; Chan, TSY; Ip, AHW; Kwong, YL; Pang, AWK	1
Barth, P; Costa, LJ; Giri, S; Olszewski, AJ	1
Hou, HA; Liu, Y; Qiu, H; Tang, CH	1
Khoury, JD; Tashakori, M	1
Becker, PS; Bensinger, W; Holmberg, LA	1
Chan, TSY; Kwong, YL; Mak, V	1
Bajaj, K; Ibrahim, M; Kapila, A; Moore, CA	1
Akashi, K; Aoki, T; Eto, T; Henzan, H; Iwasaki, H; Kamimura, T; Kohno, K; Miyamoto, T; Muta, T; Nagafuji, K; Ogawa, R; Ohno, Y; Sugio, Y; Tanimoto, K; Yamasaki, S; Yoshimoto, G	1
Bargetzi, M; Bersvendsen, H; de Nully Brown, P; Dirnhofer, S; Ferreri, AJM; Ghielmini, M; Hagberg, H; Hawle, H; Hayoz, S; Hernberg, M; Hitz, F; Johansson, AS; Kimby, E; Krasniqi, F; Lohri, A; Mey, UJM; Mingrone, W; Novak, U; Rauch, D; Rondeau, S; Vanazzi, A; Vilei, SB; Wahlin, BE; Zander, T; Zucca, E; Østenstad, B	1
Sanchorawala, V; Seldin, DC; Shelton, AC; Zeldis, JB	1
Chi, XH; Lu, XC; Yang, B; Yu, RL	1
Cosiglio, FJ; Ordi-Ros, J	1
Guo, S; Hayes, TG; Lin, D; Munker, R; Shi, R	1
Landgren, O; Mailankody, S	1
Engelhardt, M; Kleber, M; Landgren, O; Wäsch, R	1
Pratt, G	1
Anderson, K; Barlogie, B; Boccadoro, M; Bringhen, S; Cavo, M; Ciccone, G; Dimopoulos, MA; Evangelista, A; Hajek, R; Kumar, SK; Larocca, A; Lonial, S; Lupparelli, G; McCarthy, PL; Musto, P; Nooka, AK; Offidani, M; Palumbo, A; Petrucci, MT; Richardson, P; Sonneveld, P; Spencer, A; Usmani, S; van der Holt, B; Waage, A; Zweegman, S	1
Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Tarakuwa, T	1
Abe, Y; Hamano, A; Hattori, Y; Miyazaki, K; Nakagawa, Y; Sekine, R; Shingaki, S; Suzuki, K; Tsukada, N	1
Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S	1
Ali, SM; Chmielecki, J; Miller, VA; Morosini, D; Palmer, GA; Ross, JS; Sharman, JP; Stafl, J; Stephens, PJ	1
Cejalvo, MJ; de la Rubia, J	1
Areethamsirikul, N; Reece, DE	1
Anderson, KC; Ghobrial, IM; Laubach, J; Maglio, ME; Mitsiades, CS; Munshi, NC; O'Donnell, EK; Paba-Prada, C; Raje, N; Richardson, PG; Schlossman, R; Varga, C; Warren, D; Weinstock, M; Weller, E; Xie, W	1
Callander, NS; Chanan-Khan, AA; Fonseca, R; Jacobus, S; Rajkumar, SV; Stewart, AK; Weiss, M	1
Fong, R; Lo, M; Tan, M; Young, R	1
Fujii, S; Fujita, M; Kanari, Y; Kato, J; Kuroda, H; Maeda, M; Sakamoto, H; Sato, T; Shimoyama, S; Usami, M; Yamada, M; Yoshida, M	1
Andersson, BS; Berenson, JR; Champlin, RE; Chang, VT; Guan, X; Qazilbash, MH; Shen, Y; Wang, J; Wang, ML; Wang, Y; Yang, F; Zhang, W	1
Alemayehu, WG; Bos, GM; Broijl, A; Cornelisse, PB; de Weerdt, O; Kersten, MJ; Levin, MD; Lokhorst, H; Meijer, E; Sonneveld, P; Stevens-Kroef, M; Tanis, BC; Vellenga, E; Wijermans, PW; Wittebol, S	1
Abonour, R; Durie, BG; Gasparetto, C; Hardin, JW; Kenvin, L; Knight, R; Lu, JJ; Mehta, J; Nagarwala, Y; Narang, M; Rifkin, RM; Shah, JJ; Srinivasan, S; Terebelo, H; Toomey, K	1
Qian, W; Wang, B; Xu, G; Yang, M	1
Al Ali, NH; Dalton, W; Fisher, K; Fulp, W; Hampras, SS; Kenvin, L; Knight, R; Komrokji, RS; Lancet, J; Lee, JH; List, A; Olesnyckyj, M; Padron, E; Rollison, DE; Shain, KH; Xu, Q	1
Baladandayuthapani, V; Dawson, CW; Iempridee, T; Jones, RJ; Kenney, SC; Lee, HC; Lin, HC; Mertz, JE; Orlowski, RZ; Shah, JJ; Wang, X; Weber, DM	1
Alsina, M; Baz, R; Dalton, W; Fisher, K; Fulp, W; Hampras, S; Kenvin, L; Knight, R; Komrokji, R; Lee, JH; Nishihori, T; Olesnyckyj, M; Rollison, DE; Shain, KH; Sullivan, D; Xu, Q	1
Chan, TS; Khong, PL; Kwong, YL	1
Fujimi, A; Hashimoto, A; Hirayama, Y; Horiguchi, H; Ibata, S; Iyama, S; Kamihara, Y; Kato, J; Kobune, M; Konuma, Y; Kuroda, H; Miyanishi, K; Murase, K; Nagamachi, Y; Ono, K; Sato, T; Takada, K; Tatekoshi, A; Yoshida, M	1
Atenafu, EG; Chen, C; Chu, CM; Kotchetkov, R; Kukreti, V; Masih-Khan, E; Reece, DE; Tiedemann, R; Trudel, S	1
Boyd, KD; Cairns, DA; Collett, C; Cook, G; Davies, FE; Drayson, MT; Gregory, WM; Henderson, R; Jackson, GH; Jenner, M; Jones, JR; Kaiser, MF; Kishore, B; Lindsay, J; Morgan, GJ; Owen, RG; Pawlyn, C; Pratt, G; Russell, NH; Sigsworth, R; Striha, A; Williams, C	1
Bauer, F; Dasanu, CA; Reale, MA	1
Liedtke, M; Medeiros, BC	1
Landgren, O; Mailankody, S; Thomas, A	1
Reece, D; Scott, E	1
Bocchia, M; D'Arena, G; D'Auria, F; Defina, M; Gozzetti, A; Musto, P; Papini, G; Statuto, T; Steduto, T	1
Brandenburg, N; Dimopoulos, MA; Morgan, GJ; Niesvizky, R; Richardson, PG; Weber, DM; Yu, Z	1
Beksac, M; Ben Yehuda, D; Bladé, J; Cascavilla, N; Catalano, J; Cavo, M; Corso, A; Delforge, M; Dimopoulos, MA; Gisslinger, H; Hajek, R; Herbein, L; Iosava, G; Jacques, C; Kloczko, J; Kropff, M; Langer, C; Mei, J; Palumbo, A; Petrucci, MT; Plesner, T; Radke, J; Spicka, I; Weisel, K; Wiktor-Jędrzejczak, W; Yu, Z; Zodelava, M	1
Anderson, KC; Barry, S; Bashey, A; Bennett, E; Bressler, L; Callander, NS; Devine, SM; Gabriel, DA; Gentile, T; Giralt, S; Hari, P; Hars, V; Hassoun, H; Hofmeister, CC; Horowitz, MM; Hurd, DD; Isola, L; Jiang, C; Kelly, M; Landau, H; Levitan, D; Linker, C; Martin, T; Maziarz, RT; McCarthy, PL; McClune, B; Moreb, JS; Owzar, K; Pasquini, MC; Postiglione, J; Qazilbash, MH; Richardson, PG; Rosenbaum, C; Schlossman, R; Seiler, M; Shea, TC; Stadtmauer, EA; Van Besien, K; Vij, R; Weisdorf, DJ	1
Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Decaux, O; Dumontet, C; Facon, T; Garderet, L; Harousseau, JL; Hulin, C; Lauwers-Cances, V; Leleu, X; Leyvraz, S; Marit, G; Mathiot, C; Michallet, M; Moreau, P; Payen, C; Pegourie, B; Roussel, M; Stoppa, AM; Vekemans, MC; Voillat, L	1
Ahmad, N; Al Sayed, Y; Atrash, S; Barlogie, B; Chauhan, N; Crowley, J; Heuck, CJ; Hoering, A; Nair, B; Petty, N; Sexton, R; Usmani, SZ; van Rhee, F; Waheed, S	1
Lentzsch, S; Pan, B	1
Rajkumar, SV	1
Suzuki, K	2
Usmani, SZ	1
Chim, CS; Choi, PT; Lee, WK	1

Reviews

16 review(s) available for lenalidomide and Cancer, Second Primary

Article	Year
Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis. The Lancet. Haematology, 2022, Volume: 9, Issue:12 Topics: Hematologic Neoplasms; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Transplantation, Autologous	2022
B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review. BMC cancer, 2019, Nov-27, Volume: 19, Issue:1 Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Marrow; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Neoplasms, Second Primary; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Thalidomide	2019
Second malignancies in multiple myeloma; emerging patterns and future directions. Best practice & research. Clinical haematology, 2020, Volume: 33, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Neoplasms, Second Primary; Risk Factors; Thalidomide; Transplantation, Autologous	2020
Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. PloS one, 2013, Volume: 8, Issue:5 Topics: Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome	2013
[Current therapeutic indications of thalidomide and lenalidomide]. Medicina clinica, 2014, Apr-22, Volume: 142, Issue:8 Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Antineoplastic Agents; Collagen Diseases; Endocrine System Diseases; Gastrointestinal Diseases; Graft vs Host Disease; Hematologic Diseases; Humans; Immunologic Factors; Inflammation; Lenalidomide; Neoplasms; Neoplasms, Second Primary; Peripheral Nervous System Diseases; Safety-Based Drug Withdrawals; Skin Diseases; Thalidomide; Thrombophilia; Vasculitis	2014
Update on second primary malignancies in multiple myeloma: a focused review. Leukemia, 2014, Volume: 28, Issue:7 Topics: Antineoplastic Agents; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Risk; Thalidomide	2014
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. The Lancet. Oncology, 2014, Volume: 15, Issue:3 Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Thalidomide	2014
der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases. Acta haematologica, 2014, Volume: 132, Issue:2 Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Banding; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 5; Contraindications; Fatal Outcome; Female; Hematologic Neoplasms; Humans; Karyotype; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Lymphoma, T-Cell, Peripheral; Male; Megakaryocytes; Myelodysplastic Syndromes; Neoplasms, Second Primary; Recurrence; Remission Induction; Thalidomide; Translocation, Genetic	2014
Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. Future oncology (London, England), 2015, Volume: 11, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Renal Insufficiency; Risk Factors; Stem Cell Transplantation; Thalidomide	2015
The risk of secondary primary malignancies after therapy for multiple myeloma. Leukemia & lymphoma, 2015, Volume: 56, Issue:11 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Incidence; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Recurrence; Retreatment; Risk; Risk Assessment; Risk Factors; Thalidomide; Treatment Outcome	2015
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. Journal of the National Cancer Institute, 2016, Volume: 108, Issue:3 Topics: Disease-Free Survival; Humans; Immunosuppressive Agents; Infections; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasms, Second Primary; Neutropenia; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Risk; Severity of Illness Index; Survival Analysis; Survival Rate; Thalidomide; Thromboembolism	2016
Plasma cell leukemia: concepts and management. Expert review of hematology, 2010, Volume: 3, Issue:5 Topics: Aged; Antigens, CD20; Antineoplastic Agents; Boronic Acids; Bortezomib; CD56 Antigen; Humans; Lenalidomide; Leukemia, Plasma Cell; Multiple Myeloma; Neoplasms, Second Primary; Palliative Care; Paraproteinemias; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome	2010
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood, 2012, Mar-22, Volume: 119, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Incidence; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Risk Assessment; Thalidomide	2012
The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacology & therapeutics, 2012, Volume: 136, Issue:1 Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide	2012
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. Clinical and experimental nephrology, 2012, Volume: 16, Issue:5 Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide	2012
Current therapeutic strategy for multiple myeloma. Japanese journal of clinical oncology, 2013, Volume: 43, Issue:2 Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid	2013

Trials

10 trial(s) available for lenalidomide and Cancer, Second Primary

Article	Year
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood, 2019, 07-25, Volume: 134, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Second Primary; Rituximab; Symptom Assessment; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2019
Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide. American journal of hematology, 2013, Volume: 88, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Angiogenesis Inhibitors; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Risk Factors; Thalidomide	2013
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood, 2015, Sep-10, Volume: 126, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Quality of Life; Thalidomide	2015
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma. Haematologica, 2016, Volume: 101, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Lenalidomide; Logistic Models; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome	2016
A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:5 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Thalidomide; Treatment Outcome	2016
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood cancer journal, 2016, 12-09, Volume: 6, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Oligopeptides; Risk Factors; Thalidomide; Vorinostat	2016
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. The New England journal of medicine, 2012, May-10, Volume: 366, Issue:19 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Neutropenia; Prednisone; Thalidomide	2012
Lenalidomide after stem-cell transplantation for multiple myeloma. The New England journal of medicine, 2012, May-10, Volume: 366, Issue:19 Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Stem Cell Transplantation; Thalidomide	2012
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. The New England journal of medicine, 2012, May-10, Volume: 366, Issue:19 Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Stem Cell Transplantation; Thalidomide; Young Adult	2012
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood, 2012, Aug-23, Volume: 120, Issue:8 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Incidence; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Thalidomide	2012

Other Studies

38 other study(ies) available for lenalidomide and Cancer, Second Primary

Article	Year
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood, 2022, 10-20, Volume: 140, Issue:16 Topics: Genes, p53; Hematopoietic Stem Cells; Humans; Lenalidomide; Mutation; Neoplasms, Second Primary; Thalidomide; Tumor Suppressor Protein p53	2022
Secondary Hemophagocytic Syndrome in a Patient with Plasma Cell Myeloma and CNS Involvement Treated with Lenalidomide. Medicina (Kaunas, Lithuania), 2022, Sep-26, Volume: 58, Issue:10 Topics: Adult; Diagnosis, Differential; Humans; Immunomodulating Agents; Lenalidomide; Lymphohistiocytosis, Hemophagocytic; Multiple Myeloma; Neoplasms, Second Primary	2022
Lenalidomide and risk of second primary malignancy-is disease context key? The Lancet. Haematology, 2022, Volume: 9, Issue:12 Topics: Humans; Lenalidomide; Neoplasms, Second Primary	2022
Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood advances, 2023, 06-27, Volume: 7, Issue:12 Topics: Adult; Hematologic Neoplasms; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Transplantation, Autologous; United States	2023
The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm. Hematological oncology, 2019, Volume: 37, Issue:4 Topics: Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Breast Neoplasms; Combined Modality Therapy; Dendritic Cells; Dexamethasone; Drug Synergism; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lenalidomide; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Neoplasms, Second Primary; Off-Label Use; Skin Neoplasms	2019
Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report. Acta haematologica, 2020, Volume: 143, Issue:6 Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Heart Neoplasms; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Second Primary; Pericardium	2020
Unique evolution of angioimmunoblastic T cell lymphoma to Epstein-Barr virus-positive plasma cell myeloma. Annals of hematology, 2020, Volume: 99, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Etoposide; Herpesvirus 4, Human; Humans; Lenalidomide; Lymphoma, T-Cell; Male; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisolone; Vincristine	2020
Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis. Journal of geriatric oncology, 2021, Volume: 12, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Medicare; Multiple Myeloma; Neoplasms, Second Primary; United States	2021
Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan. Scientific reports, 2020, 09-01, Volume: 10, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Registries; Retrospective Studies; Risk Factors; Taiwan; Thalidomide; Treatment Outcome	2020
B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma. Blood, 2020, 12-03, Volume: 136, Issue:23 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autografts; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasms, Second Primary; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Stem Cell Transplantation	2020
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin. Acta haematologica, 2017, Volume: 137, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Combined Modality Therapy; Consolidation Chemotherapy; Dexamethasone; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Peripheral Nervous System Diseases; Thalidomide; Transplantation, Autologous; Treatment Outcome	2017
Complete radiologic and molecular response of HIV-negative primary effusion lymphoma with short-course lenalidomide. Annals of hematology, 2017, Volume: 96, Issue:7 Topics: Aged, 80 and over; DNA, Viral; Drug Eruptions; Drug Monitoring; Eosinophilia; Epstein-Barr Virus Infections; Gastrointestinal Stromal Tumors; Herpesvirus 4, Human; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Primary Effusion; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Radiography, Thoracic; Treatment Outcome; Tumor Burden	2017
Glioblastoma Multiforme in a Patient with Multiple Myeloma: A Case Report and Literature Review. The Permanente journal, 2018, Volume: 22 Topics: Aged; Glioblastoma; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Neoplasms, Second Primary	2018
Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation. International journal of hematology, 2019, Volume: 109, Issue:1 Topics: Hematopoietic Stem Cell Transplantation; Incidence; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Risk Factors; Survival Analysis; Transplantation, Autologous	2019
Multiple myeloma and other malignancies: a pilot study from the Houston VA. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:2 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Incidence; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pilot Projects; Proportional Hazards Models; Registries; Retrospective Studies; Survivors; Texas; Thalidomide; United States; United States Department of Veterans Affairs	2014
Multiple myeloma and second malignancies. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:2 Topics: Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasms, Second Primary; Registries; Thalidomide	2014
Lenalidomide and second malignancies in myeloma patients. The Lancet. Oncology, 2014, Volume: 15, Issue:3 Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Thalidomide	2014
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Immunosuppressive Agents; Lenalidomide; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyrazines; Retrospective Studies; Thalidomide; Time Factors	2014
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia. Leukemia & lymphoma, 2015, Volume: 56, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Leukemia, Plasma Cell; Neoplasms, Second Primary; Pyrazines; Thalidomide; Treatment Outcome	2015
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Dexamethasone; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Male; Mediastinal Neoplasms; Middle Aged; Multiple Myeloma; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Osteolysis; Palliative Care; Plasmacytoma; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; Remission Induction; Salvage Therapy; Sulfonamides; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vemurafenib	2014
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. British journal of haematology, 2015, Volume: 169, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Staging; Neoplasms, Second Primary; Plasmacytoma; Pyrazines; Remission Induction; Risk; Thalidomide; Treatment Outcome	2015
Lenalidomide and secondary acute lymphoblastic leukemia: a case series. Hematological oncology, 2017, Volume: 35, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Thalidomide; Treatment Outcome; Young Adult	2017
[A Newly Diagnosed Case of Multiple Myeloma in Which Lenalidomide Was Continued after Surgery for a Pancreatic Neuroendocrine Tumor That Developed during Lenalidomide Maintenance Therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:8 Topics: Aged; Female; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Pancreatic Neoplasms; Thalidomide; Tomography, X-Ray Computed	2015
Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide. Leukemia & lymphoma, 2016, Volume: 57, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Male; Meta-Analysis as Topic; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Randomized Controlled Trials as Topic; Registries; SEER Program; Thalidomide; Young Adult	2016
A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:11 Topics: Carcinoma; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms, Second Primary; Thalidomide	2015
Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. Cancer medicine, 2016, Volume: 5, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cell Transformation, Neoplastic; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Registries; Retrospective Studies; Risk Factors; Thalidomide	2016
Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Oct-01, Volume: 22, Issue:19 Topics: Animals; Cell Line, Tumor; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Neoplasms, Second Primary; Phosphatidylinositol 3-Kinases; Thalidomide; Virus Activation; Virus Latency	2016
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide. Leukemia & lymphoma, 2017, Volume: 58, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Odds Ratio; Population Surveillance; Retrospective Studies; Risk Factors; Thalidomide	2017
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma. Annals of hematology, 2016, Volume: 95, Issue:11 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Vincristine	2016
Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients. Cancer medicine, 2017, Volume: 6, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Thalidomide; Treatment Outcome	2017
Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide. Leukemia research, 2010, Volume: 34, Issue:7 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclin D1; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppression Therapy; Lenalidomide; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Second Primary; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous	2010
Myeloma and second primary cancers. The New England journal of medicine, 2011, Dec-08, Volume: 365, Issue:23 Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid; Melphalan; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Probability; Risk Assessment; Thalidomide	2011
What is the benefit of maintenance therapy with lenalidomide or bortezomib after autologous stem cell transplantation in multiple myeloma and what is the risk of developing a secondary primary malignancy? Hematology. American Society of Hematology. Education Program, 2011, Volume: 2011 Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Risk Factors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous	2011
Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia. British journal of haematology, 2012, Volume: 157, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fatal Outcome; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Neoplasms, Second Primary; Pyrazines; Recurrence; Remission Induction; Thalidomide	2012
Lenalidomide: second cancers. Prescrire international, 2012, Volume: 21, Issue:127 Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Pharmacovigilance; Thalidomide	2012
Second to none. Blood, 2012, Aug-23, Volume: 120, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Neoplasms, Second Primary; Thalidomide	2012
Second primary malignancies and myeloma therapy: fad or fact? Oncotarget, 2012, Volume: 3, Issue:9 Topics: Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Stem Cell Transplantation; Thalidomide	2012
Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide. Annals of hematology, 2013, Volume: 92, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Combined Modality Therapy; Dacarbazine; Dexamethasone; Doxorubicin; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Vincristine	2013